Article Details

Artiva Raises $120 Million to Advance Pipeline of Allogeneic NK Cell Therapies

Retrieved on: 2021-02-26 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

Artiva Raises $120 Million to Advance Pipeline of Allogeneic NK Cell Therapies. View article details on HISWAI: https://www.biospace.com/article/artiva-raises-120-million-to-advance-pipeline-of-allogeneic-nk-cell-therapies/

Excerpt

... an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers. AB-1010 is currently in a Phase I/II ...

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up